Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Bambino Gesù Hospital and Research Institute | OTHER |
| PENTA Foundation | NETWORK |
| Johns Hopkins University | OTHER |
| University of Miami |
Not provided
Not provided
Not provided
Phase I, Proof of Concept, Open-Label, Randomized Clinical Trial to Evaluate the Safety and Effects of Using Prime-boost HIVIS DNA and MVA-CMDR Vaccine Regimens with or without Toll-like Receptor 4 Agonist on HIV Reservoirs in Perinatally HIV Infected Children and Youth
HIVIS DNA and MVA-CMDR vaccines induce immune responses important for clearing infected cells: broad HIV-specific CD8+ cytotoxic T cells, potent antibodydependent cellular cytotoxicity (ADCC), and binding antibody (Ab) and neutralizing antibody (NAb). The study include early treated children because of their healthy immunity and small HIV reservoirs. Giving licensed vaccine, Cervarix®, against human papilloma virus (HPV) that contains toll-like receptor (TLR) 4 agonist with HIVIS DNA could increase DNA antigen loading on dendritic cells and promote adaptive immune responses to the HIV vaccine.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Arm 1 (n=10): HIVIS DNA / MVA-CMDR | Experimental | Arm 1 (n=10) will receive 1500 micrograms (0.5ml) HIVIS DNA IM by needle-free injection at weeks 0 and 4 followed by intramuscular (IM) needle injection of 1 X 108 IU/mL (1ml) MVA-CMDR at weeks 24 and 36 in the same arm as HIVIS DNA. Participants who have been randomized to receive HIVIS DNA and MVA-CMDR alone (ARM 1) will be administered Cervarix after week 72, the last study follow-up visit, if required. |
|
| Arm 2 (n=10): HIVIS DNA + Cervarix/ / MVA-CMDR | Experimental | Arm 2 (n=10) will receive 0.5 ml of Cervarix IM by needle injection followed by 1500 micrograms (0.5ml) per injection of HIVIS DNA IM by a needle-free injection device in the skin above (proximal to) the Cervarix injection (within 1.5 cm). They will receive 1 X 108 IU/mL (1ml) MVA-CMDR IM by needle injection at weeks 24 and 36 in the same arm as HIVIS DNA. They will also receive 0.5 ml Cervarix at the time of the first MVACMDR injection in the opposite arm from the MVA injection at week 24. |
|
| Arm 3 (n=5): Cervarix | Experimental | Arm 3 (n=5) will receive 0.5 ml of Cervarix by IM needle injection at weeks 0, 4 and 24. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| HIVIS DNA/MVA-CMDR | Biological | HIVIS DNA IM by needle-free injection at weeks 0 and 4 followed by intramuscular (IM) needle injection of 1 X 108 IU/mL (1ml) MVA-CMDR at weeks 24 and 36 in the same arm as HIVIS DNA. |
| Measure | Description | Time Frame |
|---|---|---|
| Solicited and unsolicited serious adverse events | Safety | through study completion, an average of 1 year |
| Frequencies of CD4+ T cells that produce Tat/Rev transcription (tat/rev RNA+ cells/106 CD4+ T cells) | Efficacy | Change from Baseline at week 24, 36, 48, 60, 72 |
| HIV DNA (copies/106 CD4+ T cells) | Efficacy | Change from Baseline at week 28, 48 |
| Measure | Description | Time Frame |
|---|---|---|
| Solicited and unsolicited non-serious adverse events | Safety | through study completion, an average of 1 year |
| Unspliced and multiply-spliced RNA+ cells/1000 ng cellular RNA | Efficacy |
Not provided
Inclusion criteria:
HIV perinatally infected
Know their HIV+ status
Initiated ART prior to 6 months of age
Male and female ≥ 9 years old
In generally good health
Plasma viral load < 200 copies/ml on ART at screening
CD4 count above 400 cells/mm3 at screening
Participants of childbearing potential who are sexually active must be willing to practice effective contraception during the study
Negative urine β-HCG (human chorionic gonadotropin) pregnancy test for any female of childbearing age (post-menarche)
Availability for follow-up for planned duration of the study
Passing a test of understanding is required for participants ≥ 18 years old or the parent(s)/legal representative of participants < 18 years old before consent.
Written informed consent from participants ≥ 18 years old or parent(s)/legal representative of participants < 18 years old. Assent by participants aged 9-17 years old will also be required.
Laboratory criteria within 8 weeks prior to enrollment
Exclusion criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Merlin Robb, MD | Henry M. Jackson Foundation for the Advancement of Military Medicine | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Stellenbosch University | Tygerberg Hills | Cape Town | 7505 | South Africa |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| OTHER |
| Leidos Biomedical Research, Inc. | INDUSTRY |
| Case Western Reserve University | OTHER |
| Karolinska Institutet | OTHER |
| Walter Reed Army Institute of Research (WRAIR) | FED |
| Armed Forces Research Institute of Medical Sciences, Thailand | OTHER_GOV |
| University of Padova | OTHER |
| Chulalongkorn University | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
| HIVIS DNA + Cervarix and MVA-CMDR | Biological | Cervarix IM by needle injection followed by 1500 micrograms (0.5ml) per injection of HIVIS DNA IM by a needle-free injection device in the skin above (proximal to) the Cervarix injection (within 1.5 cm). They will receive 1 X 108 IU/mL (1ml) MVA-CMDR IM by needle injection at weeks 24 and 36 in the same arm as HIVIS DNA. They will also receive 0.5 ml Cervarix at the time of the first MVACMDR injection in the opposite arm from the MVA injection at week 24. |
|
| Cervarix | Biological | Cervarix by IM needle injection at weeks 0, 4 and 24. |
|
| Week 24, 36, 48, 60, 72 |
| IUPM from total CD4+ T cells in blood by QVOA | Efficacy | Week 24, 36, 48, 60, 72 |
| Plasma HIV RNA by SCA | Efficacy | Week 24, 36, 48, 60, 72 |
| HIV-specific CD8+ and CD4+ T cells | Immunogicity | Week 28, 48 |
| ADCC | Immunogicity | Week 28, 48 |
| Binding and neutralizing Ab | Immunogicity | Week 28, 48 |
| Global gene expression on PBMCs by RNA seq | immune response | Week 28, 48 |
| Gene expression on HIV-specific CD8+ and CD4+ T cells | immune response | Week 28, 48 |
| ID | Term |
|---|---|
| D015658 | HIV Infections |
| ID | Term |
|---|---|
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D007239 | Infections |
| D015229 | Sexually Transmitted Diseases, Viral |
| D012749 | Sexually Transmitted Diseases |
| D016180 | Lentivirus Infections |
| D012192 | Retroviridae Infections |
| D012327 | RNA Virus Infections |
| D014777 | Virus Diseases |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D007153 | Immunologic Deficiency Syndromes |
| D007154 | Immune System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C510352 | human papillomavirus vaccine, L1 type 16, 18 |
Not provided
Not provided
Not provided